High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms Mutations of spliceosome genes were shown to occur frequently in different entities.
/L), and percentage of ring sideroblasts 60% (range 18-97%). Most patients had a normal karyotype (39 of 47, 83.0%) and 8 of 47 (17.0%) had various chromosomal aberrations consistent with MDS/MPN. Screening for SF3B1mut was performed by direct Sanger sequencing of exons [11] [12] [13] [14] [15] [16] . Using cDNA, a 1kb amplicon was generated with primers 5`-TGACCAGCCATCTG-GAAATC-3` (forward, exon 10) and 5`-CACCATCT-GTCCCACAACAC-3` (reverse, exon 17). Sequencing was performed with previous primers and 5`-GCTTGCCAGGACTTCTTGCT-3` (reverse, exon 14), 5`-AGCTTTTGCTGTTGTAGCCTCTG-3` (forward, exon 14). Mutation load was determined according to the ratio of mutated/wild-type in the electropherograms of forward and reverse reaction. Cases being SF3B1 unmutated by Sanger sequencing were reanalyzed with a more sensitive 454 deep-sequencing approach (NGS) on genomic DNA. The lowest detectable mutation load with NGS was about 3% (1,013 reads) and, for Sanger sequencing, 5-10% as confirmed by NGS. JAK2V617F, JAK2exon12 and MPLW515 mutations were analyzed as published previously. [9] [10] [11] Sensitivities of the assays were approximately 1%, 10%, and 5%, respectively. The frequency of SF3B1mut was 41 of 47 (87.2%). The 6 patients without SF3B1mut were reanalyzed by NGS but, despite higher sensitivity, no SF3B1mut was found. In the 41 SF3B1mut patients, 43 mutations with median mutation load of 40% (range 15-70%) were detected. The most frequent mutation was Lys700Glu (22 of 43, 51.2%), followed by Lys666Arg/Asn/Thr (7 of 43, 16.3%), Glu622Asp (4 of 43, 9.3%), His662Gln (4 of 43, 9.3%), Arg625Lys/Cys (3 of 43, 7.0%), Thr627Pro, Met784_Lys785delinsIle and a synonymous Leu575Leu (1 of 43, 2.3% each). The two double mutated cases had: i) Arg625Cys (load 45%) and Thr627Pro (load 45%); or ii) Lys700Glu (load 30%) and the synonymous Leu575Leu (load 70%) mutation. JAK2V617F was also very frequent (36 of 47, 76.6%). Twenty-five of 36 (69.4%) revealed a mutation load of 10-50%, 6 of 36 haematologica 2013; 98:e15 83.3% (5 of 6) 5 and 90.1% (10 of 11). 6 Furthermore, we and others showed SF3B1mut to occur in combination with MPLW515mut and mainly JAK2V617F. 2, 4 Overlap of SF3B1mut and JAK2V617F were present in 63.8% patients, which is much more frequent than in previous studies with 11.1% (2 of 18) 2 and 22.2% (4 of 18). 4 This is mainly related to the high frequency of JAK2V617F (76.6%) in our RARS-T cohort, rarely seen in other studies (31-100%) in 3 to 23 analyzed patients. 8 A very large recent multicenter study with 175 RARS-T patients analyzed for JAK2V617F reported a frequency of 42.9%.
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The only study of hematologic parameters in dependence of SF3B1mut in RARS-T patients detected no difference between SF3B1mut and SF3B1wt.
2 Our results confirmed this finding except that SF3B1mut cases had a significantly higher percentage of ring sideroblasts. This is comparable to results seen in MDS patients. 2 There is still ongoing discussion as to whether RARS-T is a distinct entity, or a subset of essential thrombocythemia or a progression of RARS. 7, 8 In contrast to MDS, almost no SF3B1mut were found in MPN patients, 1,13 whereas JAK2V617F is characteristic for MPN and rare in MDS.
12,14 Thus, the combination of high SF3B1mut and JAK2V617F frequencies supports the idea that RARS-T actually represents an overlap of MDS and MPN. Single RARS-T cases have been reported that developed from a pre-existing RARS through increasing JAK2V617F mutation load or the acquisition of JAK2V617F.
12,15 As we could detect both RARS-T patients with high SF3B1mut and low JAK2V617F load and vice versa, our data support the idea that RARS-T might develop from two directions. In this process, MDS patients with SF3B1mut or MPN patients with JAK2V617F might each acquire the other mutation.
In summary, our results show that RARS-T is characterized by high frequencies of SF3B1mut associated with percentages of ring sideroblasts and JAK2V617F correlated with platelet counts. Our data clearly demonstrate that the assignment of RARS-T into the WHO category "Myelodyplastic/myeloproliferative neoplasms" is not only justified based on cytomorphology, but is also reflected by molecular mutations. We strongly recommend screening for JAK2V617F and SF3B1mut in all confirmed or suspected RARS-T patients to facilitate diagnosis and distinguish RARS-T from other disease entities or reactive conditions. © F e r r a t a S t o r t i F o u n d a t i o n
